These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1179 related items for PubMed ID: 19884557

  • 1. Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial.
    Joensuu H, Bono P, Kataja V, Alanko T, Kokko R, Asola R, Utriainen T, Turpeenniemi-Hujanen T, Jyrkkiö S, Möykkynen K, Helle L, Ingalsuo S, Pajunen M, Huusko M, Salminen T, Auvinen P, Leinonen H, Leinonen M, Isola J, Kellokumpu-Lehtinen PL.
    J Clin Oncol; 2009 Dec 01; 27(34):5685-92. PubMed ID: 19884557
    [Abstract] [Full Text] [Related]

  • 2. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer.
    Joensuu H, Kellokumpu-Lehtinen PL, Bono P, Alanko T, Kataja V, Asola R, Utriainen T, Kokko R, Hemminki A, Tarkkanen M, Turpeenniemi-Hujanen T, Jyrkkiö S, Flander M, Helle L, Ingalsuo S, Johansson K, Jääskeläinen AS, Pajunen M, Rauhala M, Kaleva-Kerola J, Salminen T, Leinonen M, Elomaa I, Isola J, FinHer Study Investigators.
    N Engl J Med; 2006 Feb 23; 354(8):809-20. PubMed ID: 16495393
    [Abstract] [Full Text] [Related]

  • 3. Adjuvant capecitabine, docetaxel, cyclophosphamide, and epirubicin for early breast cancer: final analysis of the randomized FinXX trial.
    Joensuu H, Kellokumpu-Lehtinen PL, Huovinen R, Jukkola-Vuorinen A, Tanner M, Kokko R, Ahlgren J, Auvinen P, Paija O, Helle L, Villman K, Nyandoto P, Nilsson G, Pajunen M, Asola R, Poikonen P, Leinonen M, Kataja V, Bono P, Lindman H.
    J Clin Oncol; 2012 Jan 01; 30(1):11-8. PubMed ID: 22105826
    [Abstract] [Full Text] [Related]

  • 4. Trastuzumab for patients with axillary-node-positive breast cancer: results of the FNCLCC-PACS 04 trial.
    Spielmann M, Roché H, Delozier T, Canon JL, Romieu G, Bourgeois H, Extra JM, Serin D, Kerbrat P, Machiels JP, Lortholary A, Orfeuvre H, Campone M, Hardy-Bessard AC, Coudert B, Maerevoet M, Piot G, Kramar A, Martin AL, Penault-Llorca F.
    J Clin Oncol; 2009 Dec 20; 27(36):6129-34. PubMed ID: 19917839
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Capecitabine in addition to anthracycline- and taxane-based neoadjuvant treatment in patients with primary breast cancer: phase III GeparQuattro study.
    von Minckwitz G, Rezai M, Loibl S, Fasching PA, Huober J, Tesch H, Bauerfeind I, Hilfrich J, Eidtmann H, Gerber B, Hanusch C, Kühn T, du Bois A, Blohmer JU, Thomssen C, Dan Costa S, Jackisch C, Kaufmann M, Mehta K, Untch M.
    J Clin Oncol; 2010 Apr 20; 28(12):2015-23. PubMed ID: 20308671
    [Abstract] [Full Text] [Related]

  • 10. Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study.
    Untch M, Rezai M, Loibl S, Fasching PA, Huober J, Tesch H, Bauerfeind I, Hilfrich J, Eidtmann H, Gerber B, Hanusch C, Kühn T, du Bois A, Blohmer JU, Thomssen C, Dan Costa S, Jackisch C, Kaufmann M, Mehta K, von Minckwitz G.
    J Clin Oncol; 2010 Apr 20; 28(12):2024-31. PubMed ID: 20308670
    [Abstract] [Full Text] [Related]

  • 11. A multicenter randomized phase II study of sequential epirubicin/cyclophosphamide followed by docetaxel with or without celecoxib or trastuzumab according to HER2 status, as primary chemotherapy for localized invasive breast cancer patients.
    Pierga JY, Delaloge S, Espié M, Brain E, Sigal-Zafrani B, Mathieu MC, Bertheau P, Guinebretière JM, Spielmann M, Savignoni A, Marty M.
    Breast Cancer Res Treat; 2010 Jul 20; 122(2):429-37. PubMed ID: 20480225
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Phase II trial of weekly docetaxel, vinorelbine, and trastuzumab in the first-line treatment of patients with HER2-positive metastatic breast cancer.
    Infante JR, Yardley DA, Burris HA, Greco FA, Farley CP, Webb C, Spigel DR, Hainsworth JD.
    Clin Breast Cancer; 2009 Feb 20; 9(1):23-8. PubMed ID: 19299236
    [Abstract] [Full Text] [Related]

  • 14. Efficacy and safety of concurrent trastuzumab plus weekly paclitaxel-FEC as primary therapy for HER2-positive breast cancer in everyday clinical practice.
    Pernas S, Gil-Gil M, de Olza MO, Gumà A, Climent F, Petit A, Pla MJ, García-Tejedor A, López-Ojeda A, Falo C, Fernandez-Otega A, Mesia C, Pérez-Martin FJ, Urruticoechea A, Germà JR.
    Breast Cancer Res Treat; 2012 Aug 20; 134(3):1161-8. PubMed ID: 22772380
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node-positive breast cancer: 10-year follow-up of the phase 3 randomised BCIRG 001 trial.
    Mackey JR, Martin M, Pienkowski T, Rolski J, Guastalla JP, Sami A, Glaspy J, Juhos E, Wardley A, Fornander T, Hainsworth J, Coleman R, Modiano MR, Vinholes J, Pinter T, Rodríguez-Lescure A, Colwell B, Whitlock P, Provencher L, Laing K, Walde D, Price C, Hugh JC, Childs BH, Bassi K, Lindsay MA, Wilson V, Rupin M, Houé V, Vogel C, TRIO/BCIRG 001 investigators.
    Lancet Oncol; 2013 Jan 20; 14(1):72-80. PubMed ID: 23246022
    [Abstract] [Full Text] [Related]

  • 17. Multicentric, randomized phase III trial of two different adjuvant chemotherapy regimens plus three versus twelve months of trastuzumab in patients with HER2- positive breast cancer (Short-HER Trial; NCT00629278).
    Guarneri V, Frassoldati A, Bruzzi P, D'Amico R, Belfiglio M, Molino A, Bertetto O, Cascinu S, Cognetti F, Di Leo A, Pronzato P, Crinó L, Agostara B, Conte P.
    Clin Breast Cancer; 2008 Oct 20; 8(5):453-6. PubMed ID: 18952561
    [Abstract] [Full Text] [Related]

  • 18. Somatic mutation profiling and associations with prognosis and trastuzumab benefit in early breast cancer.
    Loi S, Michiels S, Lambrechts D, Fumagalli D, Claes B, Kellokumpu-Lehtinen PL, Bono P, Kataja V, Piccart MJ, Joensuu H, Sotiriou C.
    J Natl Cancer Inst; 2013 Jul 03; 105(13):960-7. PubMed ID: 23739063
    [Abstract] [Full Text] [Related]

  • 19. Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm.
    Burstein HJ, Harris LN, Marcom PK, Lambert-Falls R, Havlin K, Overmoyer B, Friedlander RJ, Gargiulo J, Strenger R, Vogel CL, Ryan PD, Ellis MJ, Nunes RA, Bunnell CA, Campos SM, Hallor M, Gelman R, Winer EP.
    J Clin Oncol; 2003 Aug 01; 21(15):2889-95. PubMed ID: 12885806
    [Abstract] [Full Text] [Related]

  • 20. Randomized, phase III trial of sequential epirubicin and docetaxel versus epirubicin alone in postmenopausal patients with node-positive breast cancer.
    Coombes RC, Bliss JM, Espie M, Erdkamp F, Wals J, Tres A, Marty M, Coleman RE, Tubiana-Mathieu N, den Boer MO, Wardley A, Kilburn LS, Cooper D, Thomas MW, Reise JA, Wilkinson K, Hupperets P.
    J Clin Oncol; 2011 Aug 20; 29(24):3247-54. PubMed ID: 21768453
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 59.